Clues to COVID-19's vulnerability emerge from an antibody
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
The study, published today in Science, is the first to map a human antibody's interaction with the new coronavirus at near-atomic-scale resolution. Although the antibody was produced in response to an infection of SARS (severe acute respiratory syndrome), which is caused by the SARS-CoV virus, it cross-reacts with the new coronavirus, SARS-CoV-2.
The structural mapping revealed a nearly identical site on both coronaviruses to which the antibody binds, suggesting a functionally important and vulnerable site for this family of coronaviruses.
"The knowledge of conserved sites like this can aid in structure-based design of vaccines and therapeutics against SARS-CoV-2, and these would also protect against other coronaviruses--including those that may emerge in the future," says the study's senior author Ian Wilson, DPhil, Hansen Professor of Structural Biology and Chair of the Department of Integrative Structural and Computational Biology at Scripps Research.
2026-09-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
-
Anke Bio and Afana Collaborate on mRNA Vaccines for Mutant Strains Such as COVID-19 Omicron
-
As Low as $25/session! Pfizer's COVID-19 Oral Drug Paxlovid Generic Drug Price Released
-
Survey On Corona Deaths By Country
-
COVID-19 Drug Remdesivir Approved for Infants And Young Children
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
Recommend Reading
-
India Imposes Anti-Dumping Duties on Rubber Chemicals from China, EU and U.S.
-
Urea Market Lacks Direction as China, Iran Supply and India Tender Shape Outlook
-
Venezuela’s Moron Petrochemical Complex Restarts as Regional Supply Risks Remain
-
$530 Million Lawsuit Unheard, $76 Million Counterclaim Filed: Is Qicai Chemical’s ‘Reputation Defense’ a Desperate Last Stand or a Calculated PR Gambit?
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
In June, the overall market for maleic anhydride in China saw a significant decline
-
December China Soda Ash Market Fluctuates
-
On October 14th, China's acetone market is expected to remain weak and difficult to adjust
-
Strong Supply-Side Support Continues to Drive Acetic Acid Prices Up in December in China
-
Poor Demand Continues to Drive Down Butadiene Market
- Hot Searches
- guar gum for incense
- reta where to buy
- para-toluidine
- who sells the best peptides
- sodium hydroxide price
- food propylene glycol
- azithromycin dihydrate api market price 2026
- polyvinyl alcohol films market
- lg chem america inc
- tirzepatide peptide buy
- ammonium nitrate price
- brand name testosterone cypionate